ASH 2017 | Strategies for treating Richter’s transformation in CLL: checkpoint inhibitors and venetoclax

Matthew Davids

Richter’s transformation remains a challenge in chronic lymphocytic leukemia (CLL). In this interview, Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the key approaches being developed to address this issue, include immunotherapy and chemosensitivity enhancement. Dr Davids discusses promising recent and ongoing studies in these areas, including those investigating immune checkpoint inhibitors and venetoclax. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Share this video